Clinical Trial: Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509099) titled 'Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC' on March 24.

Brief Summary: This is an open-label, randomized, prospective, multicenter phase III trial to evaluate the efficacy and safety of the combination therapy of cetuximab with either pembrolizumab or finotonlimab, alongside chemotherapy, as a first-line treatment, compared with pembrolizumab or finotonlimab with chemotherapy for R/M HNSCC.

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Squamous Cell Carcinoma of Head and Neck

Intervention: DRUG: cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy

Cetuximab: ...